Colon Polyps |
Colonic Polyps; What I need to know about Colon Polyps |
Clinical Trial: CHOICE: Communicating Health Options Through Information and Cancer Education
This study is currently recruiting patients.
Verified by Centers for Disease Control and Prevention August 2005
|
Purpose
| Condition | Intervention | Phase |
|---|---|---|
| Colorectal Neoplasms Rectal Neoplasms Colonic Polyps | Behavior: Academic Detailing (Med Practices)+Decision Aid (Patients) | Phase IV |
MedlinePlus related topics: Colonic Polyps; Colorectal Cancer
Study Type: Interventional
Study Design: Educational/Counseling/Training, Randomized, Single Blind, Active Control, Factorial Assignment, Efficacy Study
Official Title: Increasing CRC Screening in Health Plan Members
Secondary Outcomes: Patient’s intention to ask/patient asking medical provider for colorectal cancer screening
Expected Total Enrollment: 900
Study start: April 2005; Expected completion: April 2008
Colorectal cancer is the second most common cause of cancer death in the United States. Early detection and intervention can significantly reduce morbidity and mortality from colorectal cancer (CRC), and current guidelines recommend that asymptomatic adults over age 50 periodically obtain screening by one of several modalities (FOBT, sigmoidoscopy, colonoscopy, or double contrast barium enema). However, CRC screening remains substantially underutilized in the U.S., and more than half of all adults do not adhere to these recommendations. This study was designed to increase CRC screening among health plan members, and involves the collaboration of a major health insurer.
We will conduct a cluster-randomized trial in health practices in Georgia and North Carolina, to test the effectiveness of a decision aid (video + brochures) for increasing adherence to CRC screening guidelines. Thirty large group practices will be recruited and randomized to receive usual care (routine reminders) or an evidence-based decision aid intervention. In each practice, 30 patients between the ages of 52 and 75, without current CRC screening history, will be enrolled into the study. The intervention will continue for up to 2 years for still-unscreened participants. The main outcome will be receipt of an evidence-based modality of CRC screening according to the US Preventive Services Task Force Guidelines (FOBT, flexible sigmoidoscopy, colonoscopy, or double contrast barium enema).
Unique features of the proposed study include its potential to establish systems to increase screening uptake that will help fulfill HEDIS requirements; improving our understanding of how screening promotion interventions work in both White and Black populations; collaboration with a community partner of the Emory Prevention Research Center, and forging collaborative relationships between public health and health care researchers, and the affected communities of health plans and health care providers.
Eligibility
Accepts Healthy Volunteers
Inclusion Criteria:
- Age 52-75
- Aetna Health Plan Member
- Average Risk for Colorectal Cancer
- Did not have colorectal cancer screening within guideline timeframe (1 to 10 years, depending on individual’s age and type of screening)
Exclusion Criteria:
- History of colorectal cancer, polyps, inflammatory bowel disease, upper or lower gastrointestinal bleeding, cirrhosis, chronic obstructive pulmonary disease, cancer, blindness, uncorrectable hearing loss, severe dementia, several heart failure, severe coronary artery disease
- Family History of colorectal cancer/polyps
Location and Contact Information
Karen Glanz, PhD, MPH 404-727-7536 kglanz@sph.emory.edu
Georgia
Emory University Rollins School of Public Health, Atlanta, Georgia, 30322, United States; Recruiting
Karen Glanz, PhD, MPH 404-727-7536 kglanz@sph.emory.edu
Karen Glanz, PhD, MPH, Principal Investigator
Tracy Scott, PhD, Sub-Investigator
Michael Pignone, MD, MPH, Sub-Investigator
Barbara Rimer, DrPH, Sub-Investigator
Karen Glanz, PhD, MPH, Principal Investigator, Emory University
More Information
Last Updated: August 24, 2005
Record first received: August 23, 2005
ClinicalTrials.gov Identifier: NCT00134589
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-08-30

Not Signed In -


